Amyloidosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Veröffentlicht von: precision business insights
Veröffentlicht am: 28.03.2018 08:32
Rubrik: Gesundheit & Medizin


(Presseportal openBroadcast) - Amyloidosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Pressekontakt:

Amyloidosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Amyloidosis Pipeline Drugs Assessment

Overview:
Amyloidosis is a rare disease, which occurs due to deposition of amyloid in organs. It is an abnormal protein, produced in the bone marrow and accumulates at any part of the tissue or organ. Amyloidosis may affect different parts of the body in different people. Amyloidosis affects heart, kidney, liver, spleen and nervous system.
Amyloidosis is diagnosed with the laboratory tests by identifying the abnormality in the protein in blood and urine. Furthermore, imaging techniques and biopsy may be performed to diagnose the disease and presence of amyloidosis.
Treatment is given to relive the symptoms and limit the further production of amyloid. Treatment depends on the type of amyloidosis. Chemotherapeutic agents are used to treat the immunoglobulin light chain amyloidosis and therapies may include autologous blood stem cell transplant. AA amyloidosis is treated by treating underlying condition for example, anti inflammatory drugs for treating rheumatoid arthritis. For Hereditary amyloidosis, liver transplant may be an option.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/amyloidosis-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:
Amyloidosis pipeline drugs are segmented based on route of administration, trial phase,and company
By type, Amyloidosis pipeline drugs are segmented into
• AL Amyloidosis
• AA amyloidosis
• Others
By trial phase, Amyloidosis pipeline drugs are segmented into
• Pre-clinical phase
• Phase-I
• Phase II
• Phase-III
By company, Amyloidosis pipeline drugs are segmented into
• GLAXOSMITHKLINE PLC (U.K.)
• AMGEN INC. (U.S.)
• ALNYLAM PHARMACEUTICALS, INC., (U.S.)
• BELLUS HEALTH INC. (CANADA)
• ARCTURUS THERAPEUTICS (U.S.)
• JOHNSON & JOHNSON SERVICES INC. (U.S.)
• IONIS PHARMACEUTICALS, INC. (U.S.)

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/amyloidosis-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu


Space Analysis:
• In September 2017 Sanofi and Alnylam Pharmaceuticals reported positive results in late-stage trial of a treatment for hereditary ATTE Amyloidosis patients with polyneuropathy

Report Description:
AmyloidosisPipeline Drugs Assessment report studies the various therapeutics under clinical development for Amyloidosis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Amyloidosis pipeline drugsdevelopment. This report studies the dynamics of the AmyloidosisPipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Amyloidosis pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/amyloidosis-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3



Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on each drug candidates in the clinical trial phases

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/amyloidosis-pipeline-drugs-assessment/
About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com


Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.